SARS-CoV-2研究相關(guān)細(xì)胞產(chǎn)品及信息

隨著國(guó)內(nèi)新冠病毒肺炎疫情的持續(xù)向好，我們已經(jīng)從“抗疫”轉(zhuǎn)變?yōu)?ldquo;防疫”狀態(tài)，而與此同時(shí)，國(guó)外疫情卻還處于爆發(fā)階段。為了控制SARS-CoV-2 (2019-nCoV)，無數(shù)科研工作者就開始了爭(zhēng)分奪秒的科研攻關(guān)，圍繞新冠病毒做了大量的研究。

為助力新型冠狀病毒的相關(guān)研究和檢測(cè)，普諾賽（Procell）總結(jié)提煉了新型冠狀病毒研究相關(guān)的細(xì)胞產(chǎn)品，并將細(xì)胞相關(guān)的參考信息匯總?cè)缦?，希望能為廣大科研工作者帶來一點(diǎn)幫助。

主要包括以下內(nèi)容：

●已被證實(shí)可用于擴(kuò)增SARS-CoV-2的細(xì)胞系

●已被證實(shí)不適合擴(kuò)增SARS-CoV-2的細(xì)胞系

●基于細(xì)胞宿主的疫苗相關(guān)細(xì)胞系

*歡迎各位老師提供更多相關(guān)的附加信息、更正、更新，我們將及時(shí)更新完善。聯(lián)系郵箱：techsupport@procell.com.cn

已被證實(shí)可用于擴(kuò)增SARS-CoV-2的細(xì)胞

1.Vero 系列

以下3個(gè)“Vero”系列的細(xì)胞系被廣泛應(yīng)用于SARS-CoV-2的培養(yǎng)擴(kuò)增（按照SARS-CoV-2增殖效果遞減順序展示）。

1.1 Vero C1008（更常被稱為Vero E6，細(xì)胞系產(chǎn)品推薦：CL-0491）

參考文獻(xiàn)：

[1]. Matsuyama et al. (PubMed=32165541): "However, the viral RNA copies in the VeroE6/TMPRSS2 cell culture supernatants were >100 times greater than those from VeroE6 cells."

查看更多>>

1.2 Vero （細(xì)胞系產(chǎn)品推薦：CL-0242）

參考文獻(xiàn)：

[1]. Harcourt et al. (DOI=10.1101/2020.03.02.972935): "We found that the virus replicates to high titer in Vero-CCL81 cells and Vero E6 cells in the absence of trypsin." (also see figure 3A)

查看更多>>

1.3 VeroE6/TMPRSS2

參考文獻(xiàn)：

Matsuyama et al. (PubMed=32165541): "VeroE6/TMPRSS2 cells are superior to other cell lines tested in this study for SARS-CoV-2 isolation."

2.其他系列

2.1 Caco-2 （細(xì)胞系產(chǎn)品推薦：CL-0050）

參考文獻(xiàn)：

According to Kim et al. (PubMed=32149036): "The SARS-CoV-2 could replicate in other cells (Vero E6 and Caco-II cells), in addition to Vero cells (data not shown)."

2.2 Calu-3 （細(xì)胞系產(chǎn)品推薦：CL-0054)

參考文獻(xiàn)：

[1]. According to Matsuyama et al. (PubMed=32165541): "the amount of SARS-CoV-2 RNAs in the culture supernatants of Vero, Calu-3, and A549 cells 48 h p.i. was low."

查看更多>>

2.3 HEK293T （細(xì)胞系產(chǎn)品推薦：CL-0005）

參考文獻(xiàn)：

Harcourt et al. (DOI=10.1101/2020.03.02.972935): "both HUH7.0 and 293T cells showed only modest viral replication" (also see figure 3A).

2.4 Huh-7 （細(xì)胞系產(chǎn)品推薦：CL-0120）

參考文獻(xiàn)：

[1]. According to Harcourt et al. (DOI=10.1101/2020.03.02.972935): "both HUH7.0 and 293T cells showed only modest viral replication" (also see figure 3A).

查看更多>>

2.5 LLC-MK2 （細(xì)胞系產(chǎn)品推薦：CL-0141）

參考文獻(xiàn)：

Ou et al. (PubMed=32221306): "LLCMK2 cells, a rhesus monkey kidney epithelium cell line, exhibited different susceptibility to SARS-CoV S and SARS-CoV-2 S transduction, but the reasons for this are currently not known and require further investigation."

已被證實(shí)不適合擴(kuò)增SARS-CoV-2的細(xì)胞系

A-549 （細(xì)胞系產(chǎn)品推薦：CL-0016）

參考文獻(xiàn)：

[1]. According to Matsuyama et al. (PubMed=32165541): "the amount of SARS-CoV-2 RNAs in the culture supernatants of Vero, Calu-3, and A549 cells 48 h p.i. was low."

查看更多>>

Efk3B from bat

參考文獻(xiàn)：

Harcourt et al. (DOI=10.1101/2020.03.02.972935): "In addition, SARS-CoV-2 failed to replicate in the bat EFK3B cells which are susceptible to MERS-CoV." (also see figure 3A).

基于細(xì)胞宿主的疫苗相關(guān)細(xì)胞系

一些公司和研究機(jī)構(gòu)正在全力研發(fā)基于細(xì)胞的SARS-CoV-2疫苗。以下細(xì)胞系是這類研究中需要用到的：

CHO-K1（細(xì)胞系產(chǎn)品推薦：CL-0062) 或其衍生物中的一種可被用于CSIRO: (https://www.theage.com.au/national/coronavirus-outbreak-how-the-covid-19-vaccine-is-being-made-20200220-p542rh.html)"On February 21 the team's vaccine draft was sent to the CSIRO's manufacturing facility in the Melbourne suburb of Clayton, and manufacturing of a pilot dose began. The facility houses a 200-litre fermenting vat that will be filled with a "soup" of Chinese hamster ovary cells - the best cells for the task - in a nutritious goo."

Sorrento 使用的是K-562（細(xì)胞系產(chǎn)品推薦：CL-0130）Therapeutics, Inc.(DOI=https://doi.org/10.1016/j.medidd.2020.100026): see Ji et al: "Engineered Spike-1 protein is expressed on the surface of K562 human myelogenous leukemia cells via introduction of expression constructs into the cellular genome allowing for stable expression of the transgene. Stable-modified K562 clones are selected, profiled for Spike-1 expression as well as overall immunogenic potency, and prepared as GMP master cell bank to be used for large scale manufacturing. Irradiated cells are formulated as vaccine product and administered via intramuscular or subcutaneous injection."

PER.C(https://www.jnj.com/coronavirus): "Johnson & Johnson is mobilizing resources of its Janssen Pharmaceutical Companies in response to the outbreak to develop a possible preventive vaccine candidate against SARS-CoV-2, leveraging Janssen's AdVac (R) and PER.C6 (R) technology, that provide the ability to rapidly upscale production of the optimal vaccine candidate."